FDA Drug Label
MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information
Eli, 2022
GLP-1 & MetabolicFDA ApprovedS
Tirzepatide
Mounjaro / Zepbound
Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is Eli Lilly's FDA-approved dual GLP-1/GIP receptor agonist and the first approved twincretin therapy. SURMOUNT-1 trial demonstrated up to 22.5% average body weight reduction at 72 weeks with 15mg — the highest efficacy among approved obesity medications at time of approval. Also approved for obstructive sleep apnea reduction (2024).
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- S
- Experience
- 10
- Activity
- 64
Overall check-ins
Trackers & reports
Overview
About Tirzepatide
Tirzepatide (Mounjaro for T2D, Zepbound for obesity) is Eli Lilly's FDA-approved dual GLP-1/GIP receptor agonist and the first approved twincretin therapy. SURMOUNT-1 trial demonstrated up to 22.5% average body weight reduction at 72 weeks with 15mg — the highest efficacy among approved obesity medications at time of approval. Also approved for obstructive sleep apnea reduction (2024).
- Category
- GLP-1 & Metabolic
- Regulatory status
- FDA Approved
- Also known as
- Mounjaro / Zepbound
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 0% · Mixed 0% · Unfavorable overall 100%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
6
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
3
Injection site irritation
3
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 0.4 to ≥ 2 mg (open-ended top bucket)
0.4–0.6 mg
1
2+ mg
5
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (2)
Source
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Jastreboff et al., 2022
Tools
Explore more
Explore
More ways to learn about Tirzepatide from observational PeptIQ data.
Help
Frequently asked
What do PeptIQ users report about Tirzepatide?
This page summarizes 6 anonymized self-reports from PeptIQ users who track Tirzepatide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for Tirzepatide?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for Tirzepatide?
2 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Tirzepatide safe to use?
This wiki does not assess safety or recommend use. Tirzepatide is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Tirzepatide?
Research, primarily in animal models, suggests Tirzepatide may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Tirzepatide?
Tirzepatide is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Tirzepatide as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Tirzepatide?
The safety and effectiveness of Tirzepatide have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Tirzepatide?
While there are over 200 published studies on Tirzepatide, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source